89BIO (ETNB)
(Delayed Data from NSDQ)
$8.86 USD
+0.39 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.85 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.86 USD
+0.39 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $8.85 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy
by Zacks Equity Research
89BIO (ETNB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
by Zacks Equity Research
Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
by Zacks Equity Research
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
89BIO (ETNB) Just Overtook the 200-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for 89BIO (ETNB) points to a 168.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
by Zacks Equity Research
Data from a mid-stage study shows that Akero Therapeutics' (AKRO) lead candidate failed to achieve statistical significance in its primary endpoint of fibrosis improvement in cirrhotic NASH patients.
ASLAN (ASLN) Down 25% on Mixed Results From Skin Disease Study
by Zacks Equity Research
ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.
Are Medical Stocks Lagging 89BIO (ETNB) This Year?
by Zacks Equity Research
Here is how 89BIO (ETNB) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
by Zacks Equity Research
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
89BIO (ETNB) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for 89BIO (ETNB) points to a 57.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Allogene Therapeutics (ALLO) and 89BIO (ETNB) have performed compared to their sector so far this year.
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Wall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for 89BIO (ETNB) points to a 79.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.
89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
by Zacks Equity Research
Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.
Wall Street Analysts See an 80% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for 89BIO (ETNB) points to an 80% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug
by Zacks Equity Research
Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Allogene's (ALLO) fourth-quarter earnings beat estimates but sales come in line.
Zacks.com featured highlights Coty, OneSpaWorld, Mueller Water Products and 89BIO
by Zacks Equity Research
Coty, OneSpaWorld, Mueller Water Products and 89BIO have been highlighted in this Screen of The Week article.
4 Best Breakout Stocks to Buy for Superb Returns
by Tirthankar Chakraborty
Coty (COTY), OneSpaWorld (OSW), Mueller Water Products (MWA) and 89BIO (ETNB) have been selected as the breakout stocks for today.
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.